Branch Retinal Vein Occlusion (BRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.

Sponsor
He Eye Hospital
Study ID
NCT04601688
Status
Unknown

Conditions

  • Branch Retinal Vein Occlusion

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab Ophthalmic and Intravitreal Dexamethasone — DRUG
    Pro re nata patients with BRVO will initially receive Bevacizumab and intravitreal Dexamethasone. And then depending on their clinical status of BRVO, Bevacizumab will be injected.
  • Bevacizumab Ophthalmic — DRUG
    Pro re nata patients with BRVO will receive Bevacizumab. And then depending on their clinical status of BRVO, Bevacizumab will be injected.

Study Details

The aim of this study is to evaluate the visual outcome and prognostic factors after intraocular injections of Bevacizumab or combination of Bevacizumab And Dexamethasone under pro re nata treatment regimen for Branch Retinal Vein Occlusion (BRVO) patients.

Key Dates

First listed
Oct 26, 2020
Start date
Oct 31, 2020
Status verified
Oct 2020
Primary completion
Mar 2, 2021
Completion
Sep 17, 2021

Study Design

Enrollment
100 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: BRVO: Bevacizumab and intravitreal Dexamethasone
    Participants with BRVO will receive a combination of Bevacizumab and intravitreal Dexamethasone.
  • Active Comparator: BRVO: Bevacizumab
    Participants with BRVO will receive Bevacizumab only.

Primary Outcome Measure

Mean change in monocular BCVA in the treatment eye [ Time Frame: Baseline, 1 week, 1month, 2 months, 3 months, and 6 months. ]

Central Contacts